Raymond James analyst Steven Seedhouse reiterated a Sell rating on Madrigal Pharmaceuticals (MDGL) yesterday. The company’s shares closed last Friday at $130.42.
According to TipRanks.com, Seedhouse is a 3-star analyst with an average return of 3.6% and a 41.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Alexion Pharmaceuticals, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Madrigal Pharmaceuticals with a $172.09 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $142.62 and a one-year low of $85.52. Currently, Madrigal Pharmaceuticals has an average volume of 135.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
